Accessibility Menu
Shionogi & logo

Shionogi &(OTC) SGIOF

Current Price$17.45
Market Cap$14.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+311%
5 Year+9%
1 Year+10%
1 Month-7%
Shionogi & last closing stock price
MetricPriceDate
Last closeUSD 17.452026-07-24
Shionogi & stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.57%USD 17.552026-07-16
1 month-7.18%USD 18.802026-06-23
3 month-8.64%USD 19.102026-04-22
Year to date+16.11%USD 15.032025-12-30
1 year+10.31%USD 15.822025-07-24
3 year+33.94%USD 13.032023-07-18
5 year+9.36%USD 15.962021-07-23
Since inception+311.07%USD 4.252003-06-30

Shionogi & Financials at a Glance

Market Cap

$14.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥502.78B

Net Income (TTM)

¥206.34B

EPS (TTM)

$1.59

P/E Ratio

10.95

Dividend

$0.46

Beta (Volatility)

0.21 (Low)

Price

$17.45

Volume

1,400

Open

$17.95

Previous Close

$17.45

Daily Range

$17.45 - $17.95

52-Week Range

$14.25 - $26.00

Estimated Earnings Date

Aug 3, 2026

SGIOF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shionogi &

Shionogi & Co., Ltd. is a Japanese pharmaceutical company dedicated to the research, development, and manufacturing of innovative medical products. The company focuses on addressing various health challenges through its extensive portfolio of medications and ongoing research initiatives.

Products and Services
  • Fetroja, a treatment for multidrug-resistant bacterial infections
  • Xofluza, an antiviral medication for influenza
  • Tivicay, used in HIV management
Growth Outlook
  • Strong pipeline with multiple investigational therapies for various conditions
  • Recent collaborations with academic institutions enhance research capabilities
  • Focus on COVID-19 therapeutics positions the company for future growth
Financial Highlights
  • Recent quarterly revenue of 139.87 billion JPY, showcasing strong market demand
  • Net income of 47.23 billion JPY, reflecting robust profitability
  • TTM P/E ratio of 11.43 indicates potential value for investors
Shionogi & Co., Ltd. has established itself as a key player in the pharmaceutical industry, with a commitment to innovation and patient care. The company's diverse product offerings and strong research pipeline position it well for future growth. Recent financial performance highlights, including significant revenue and net income, underscore the company's operational strength. With ongoing investments in research and development, Shionogi is poised to continue making impactful contributions to healthcare.
AI Generated • Jun 28, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

6,223

CEO

Isao Teshirogi, PhD

Website

www.shionogi.com/jp/ja

Headquarters

Osaka, OS 541-0045, JP

SGIOF Financials

Key Financial Metrics (TTM)

Gross Margin

82.38%

Operating Margin

32.06%

Net Income Margin

41.06%

Return on Equity

13.65%

Return on Capital

6.81%

Return on Assets

7.96%

Earnings Yield

9.13%

Dividend Yield

2.65%

Payout Ratio

27.38%

Stock Overview

Market Cap

$14.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

850.98M

Volume

1.40K

Avg. Volume

1.86K

Financials (TTM)

Gross Profit

¥413.69B

Operating Income

¥162.36B

EBITDA

¥253.18B

Operating Cash Flow

¥215.09B

Capital Expenditure

-¥14.56B

Free Cash Flow

¥200.52B

Cash & ST Invst.

¥715.87B

Total Debt

¥688.70B

Shionogi & Performance Analysis

Shionogi & annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 3,149,822,8305.6%
20242024-03-31JPY 3,012,746,258-4.4%
20252025-03-31JPY 2,874,824,175-4.6%
20262026-03-31JPY 3,315,880,85915.3%
Shionogi & sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-1.2%
Q22025-09-3014.5%
Q32025-12-3128.8%
Q42026-03-31-5.4%
Shionogi & annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 1.5336.1%
20242024-03-31JPY 1.29-15.7%
20252025-03-31JPY 1.311.9%
20262026-03-31JPY 1.6021.8%
Shionogi & sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-309.5%
Q22025-09-3014.5%
Q32025-12-3166.8%
Q42026-03-31-36.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

¥139.87B

+37.8%

Gross Profit

¥106.99B

+28.4%

Gross Margin

76.50%

N/A

Market Cap

$14.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.39M

N/A

Employees

6,223

N/A

Net Income

¥47.23B

+33.0%

EBITDA

¥38.75B

-24.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

¥715.87B

+11.0%

Total Debt

¥688.70B

+3047.3%

Accounts Receivable

¥160.78B

+33.4%

Inventory

¥100.02B

+52.8%

Long Term Debt

¥19.01B

+3.2%

Short Term Debt

¥669.69B

+19104.8%

Return on Assets

7.96%

N/A

Return on Invested Capital

9.16%

N/A

Free Cash Flow

¥84.99B

+27.7%

Operating Cash Flow

¥90.61B

+23.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SONVYSonova Holding AG
$51.51+0.78%
FMCQFFresenius Medical Care AG
$48.85+0.00%
BIOVFSwedish Orphan Biovitrum AB (publ)
$49.03+0.00%
CHJTFCSPC Pharmaceutical Group Limited
$1.07+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About SGIOF

What is the current price of Shionogi &?

Shionogi & is trading at $17.45 per share.

What is the 52-week range for Shionogi &?

Over the past 52 weeks, Shionogi & has traded between $14.25 and $26.00.

How much debt does Shionogi & have?

As of the most recent reporting period, Shionogi & reported total debt of ¥4.30B.

How much cash does Shionogi & have on hand?

Shionogi & reported ¥4.47B in cash and cash equivalents in its most recent financial results.

What is Shionogi &’s dividend yield?

Shionogi & currently has a dividend yield of 2.65%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services